<DOC>
	<DOCNO>NCT00409539</DOCNO>
	<brief_summary>SMP-986 compound develop treatment overactive bladder syndrome ( OABS ) . This clinical study design test hypothesis SMP-986 dose 20mg , 40mg , 80mg 120mg provide great symptom relief OABS compare placebo . The hypothesis test measure change mean voids/24 hr treatment SMP-986 compare placebo , well compare change : severity urgency episode , mean number urgency episodes/24 hr , mean number incontinence episodes/24 hr mean void volume/void SMP-986 placebo .</brief_summary>
	<brief_title>SMP-986 Phase 2 Proof Concept Patients With Overactive Bladder Syndrome ( OABS )</brief_title>
	<detailed_description>A multicenter study conduct patient OABS comprise 2-week single blind placebo run-in period follow 8-week randomized , double-blind , placebo control treatment period patient randomize receive 20 mg , 40 mg , 80 mg 120 mg SMP 986 placebo 1:1:1:1:1 ratio parallel group outpatient basis study center visit .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<criteria>Main Males , females childbearing potential Aged 2080 year ( inclusive ) diagnosis OABS base symptomatic reporting period 6 month ( micturition frequency , urgency without incontinence ) prior screen . Main Patients exclude indication bladder outlet obstruction polyuria Patients follow condition , undergone follow procedure , exclude : stress urinary incontinence pelvic organ prolapse ( stage 2 ) genitourinary low bowel surgery ( within 12 month prior screen ) , pathological condition include poorly control diabetes , painful bladder syndrome/interstitial cystitis history chronic urinary tract infection neurological condition include multiple sclerosis , Parkinson 's disease neuropathy ) Patients also exclude indwell catheter perform intermittent self catheterisation Patients current past medical condition contraindicating use antimuscarinics must discontinue use follow drug : drug use treat OABS urinary incontinence cholinergics anticholinergic alpha adrenergic antagonist opioid analgesic compound analgesic contain opioid warfarin Patients current past malignancy ( within last 5 year ) Patients ever tumour affect genitourinary tract ( include benign prostatic hyperplasia ) exclude . Patients ineligible clinically significant cardiac , neurological , hepatic , renal , respiratory , haematological gastrointestinal disorder ( include , significant history constipation active bowel disease e.g . inflammatory bowel disease ) illness opinion Investigator would preclude safe compliant participation subject . Patients exclude unable complete study diary</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>